Severe Hypertriglyceridemia (sHTG) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Severe Hypertriglyceridemia (sHTG) Market Outlook

Thelansis’s “Severe Hypertriglyceridemia (sHTG) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Severe Hypertriglyceridemia (sHTG) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Severe Hypertriglyceridemia (sHTG) Overview

Hypertriglyceridemia is a prevalent metabolic disorder characterized by elevated levels of triglycerides, a type of fat, in the bloodstream. It is a triglyceride concentration greater than 150 mg/dL in the blood. This condition has been linked to various diseases, including atherosclerosis, obesity, and insulin resistance, increasing the risk of cardiovascular disease (CVD). Severe hypertriglyceridemia (sHTG), defined as fasting triglyceride concentrations above 10.0 mmol/L, can be classified into two categories: 1. Polygenic hypertriglyceridemia (also known as type V hyperlipoproteinemia according to the Fredrickson classification) is caused by a combination of genetic, demographic, and clinical factors, including obesity, diabetes mellitus, untreated hypothyroidism, alcohol consumption, and certain medications. 2. Familial chylomicronemia syndrome (also known as type I hyperlipoproteinemia, according to the Fredrickson classification) is a genetic disorder. Both forms are associated with elevated fasting chylomicronemia and very low-density lipoprotein levels. Familial chylomicronemia syndrome tends to be more severe and resistant to treatment. The clinical symptoms of severe hypertriglyceridemia with chylomicrons include abdominal pain and acute pancreatitis. The biochemical thresholds for hypertriglyceridemia are: normal (<1.7 mmol/L), borderline high (1.7 to 2.3 mmol/L), high (2.3 to 5.6 mmol/L), and very high (>5.6 mmol/L). A triglyceride level greater than 10.0 mmol/L is considered severely elevated and increases the risk of pancreatitis. Severe hypertriglyceridemia is usually diagnosed through a routine blood test known as a lipid profile. The risk factors for severe hypertriglyceridemia include genetic disorders, obesity, untreated diabetes, and certain medications. Individuals with extremely high levels of triglycerides may experience symptoms such as abdominal pain, nausea, vomiting, yellow-colored skin bumps (xanthomas), and acute pancreatitis.

• More than 2.1 million adults in the USA have severe hypertriglyceridemia (sHTG).

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: